Healixa Inc. announces that Christopher Galliano will join its Board of Directors as a non-executive independent Director effective January 11, 2022, demonstrating the company's focus on corporate governance, growth and national list requirements. Mr. Galliano currently serves as Chief Technology Officer and Co-Founder of Skymount Medical, where he co-authored over 6 patents in artificial intelligence based drug discovery and leads the day to day research to construct an oral therapeutic for COVID-19 and 12 other active inventions/pharmaceutical developments.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0799 USD | -0.12% | -1.24% | -71.46% |
1st Jan change | Capi. | |
---|---|---|
-71.46% | 56.97M | |
+14.43% | 3,197B | |
+14.18% | 89.6B | |
+8.75% | 80.08B | |
-13.37% | 55.52B | |
+22.60% | 46.79B | |
+32.14% | 46.34B | |
-30.71% | 43.95B | |
+71.93% | 41.34B | |
-2.58% | 26.5B |
- Stock Market
- Equities
- EMOR Stock
- News Healixa Inc.
- Healixa, Inc. Appoints Christopher Galliano as Independent Director to its Board